Ruben Pio


Affiliation: University of Navarra
Country: Spain


  1. Pio R, Agorreta J, Montuenga L. Prognostic signature of early lung adenocarcinoma based on the expression of ribonucleic acid metabolism-related genes. J Thorac Cardiovasc Surg. 2015;150:986-92.e1-11 pubmed publisher
    ..The RNA metabolism signature is a prognostic marker that may be useful for predicting survival and optimizing the benefit of adjuvant chemotherapy in patients with lung adenocarcinoma. ..
  2. Pio R, Blanco D, Pajares M, Aibar E, Durany O, Ezponda T, et al. Development of a novel splice array platform and its application in the identification of alternative splice variants in lung cancer. BMC Genomics. 2010;11:352 pubmed publisher
    ..This methodology enables the detection of alternative splicing events in complex biological samples, providing a powerful tool to identify novel diagnostic and prognostic biomarkers for cancer and other pathologies. ..
  3. Aramburu A, Zudaire I, Pajares M, Agorreta J, Orta A, Lozano M, et al. Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations. BMC Genomics. 2015;16:752 pubmed publisher
    ..Using it, we found new prognostic scores based on tumor DNA that, jointly with clinical information, are able to predict overall survival (OS) in patients with early-stage ADC and SCC. ..
  4. Ajona D, Zandueta C, Corrales L, Moreno H, Pajares M, Ortiz Espinosa S, et al. Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-mediated Effects. Am J Respir Crit Care Med. 2018;: pubmed publisher
    ..This study unveils the role played by the C5a/C5aR1 axis in lung cancer dissemination, and supports its potential use as a novel therapeutic target. ..
  5. Berraondo P, Minute L, Ajona D, Corrales L, Melero I, Pio R. Innate immune mediators in cancer: between defense and resistance. Immunol Rev. 2016;274:290-306 pubmed publisher
  6. Pio R, Elsasser T, Martinez A, Cuttitta F. Identification, characterization, and physiological actions of factor H as an adrenomedullin binding protein present in human plasma. Microsc Res Tech. 2002;57:23-7 pubmed
    ..The elucidation of the mechanisms that modulate AM activity will be necessary for the understanding of the role of AM in normal and pathological conditions. ..
  7. Pio R, Zudaire I, Pino I, Castaño Z, Zabalegui N, Vicent S, et al. Alpha CP-4, encoded by a putative tumor suppressor gene at 3p21, but not its alternative splice variant alpha CP-4a, is underexpressed in lung cancer. Cancer Res. 2004;64:4171-9 pubmed
    ..Finally, induction of alpha CP-4 expression reduced cell growth, in agreement with its proposed role as a tumor suppressor, and suggesting an association of this RNA-binding protein with lung carcinogenesis. ..
  8. de Miguel F, Pajares M, Martínez Terroba E, Ajona D, Morales X, Sharma R, et al. A large-scale analysis of alternative splicing reveals a key role of QKI in lung cancer. Mol Oncol. 2016;10:1437-1449 pubmed publisher
    ..11-5.46, P = 0.026). In conclusion, we identified several splicing variants with functional relevance in lung cancer largely regulated by the splicing factor QKI, a tumor suppressor associated with prognosis in lung cancer. ..
  9. Ajona D, Ortiz Espinosa S, Moreno H, Lozano T, Pajares M, Agorreta J, et al. A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis. Cancer Discov. 2017;7:694-703 pubmed publisher
    ..i>Cancer Discov; 7(7); 694-703. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 653. ..

More Information


  1. Ajona D, Ortiz Espinosa S, Pio R. Complement anaphylatoxins C3a and C5a: Emerging roles in cancer progression and treatment. Semin Cell Dev Biol. 2019;85:153-163 pubmed publisher